Trials
1 active
2 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “15 participants will be randomized to receive CTH120 placebo hard capsules. Capsules of CTH120 matching placebo will be administered by the oral route to participants twice a day, one capsule in the morning and one capsule in the evening, at approximately the same times each day, after breakfast (morning dose) and after dinner (evening dose), with a glass of water. The evening dose will be taken…”In the company’s words, NCT07654114 on ClinicalTrials.gov
- Tested for
- Fragile X Syndrome (FXS), Fragile X Syndrome
- Main trialPhase 2
- “The purpose of this Phase IIa study is to evaluate the safety, tolerability, and effectiveness of CTH120 in adult males with Fragile X syndrome.”In the company’s words, NCT07654114 on ClinicalTrials.gov
Other drugs for Fragile X Syndrome (FXS)
- ZatolmilastTetra Discovery Partners · Phase 3
- CodabakalnerSpinogenix · Phase 2/3
- ZYN002Harmony Biosciences · Phase 2/3
- MRM-3379Mirum Pharmaceuticals, Inc. · Phase 2
- SRX246Azevan Pharmaceuticals · Phase 2
- S247240Institut de Recherches Internationales Servier (I.R.I.S.) · Phase 2
Coming up1
- May 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | May 2027 | Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome | |
| Phase 1Completed | 11 Nov 2024 | CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026